NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.
Ohr Pharmaceutical Presentation Details |
|Date:||Monday, March 6|
|Time:||4:40pm Eastern Time|
|Location:||Regis Ballroom, 3rd Floor|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 email@example.com LifeSci Advisors, LLC Michael Wood 646-597-6983 firstname.lastname@example.org